Revalesio’s RNS60 demonstrates promise in first human asthma trial

Date: October 31, 2011

Tacoma, WA – Revalesio Corporation will present clinical efficacy and safety data for RNS60 at the annual ACAAI meeting in Boston, November 3-8. ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5,000 members devoted to the specialty of allergy and immunology.

Read More…